| Serial Number | 97152382 |
| Word Mark | QFIDYN |
| Filing Date | Thursday, December 2, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, February 20, 2024 |
| Registration Number | 7307766 |
| Registration Date | Tuesday, February 20, 2024 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, December 5, 2023 |
| Goods and Services | Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, December 6, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CSL Behring GmbH |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Party Name | CSL Behring GmbH |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Marburg D-35041 DE |
| Event Date | Event Description |
| Tuesday, February 20, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, February 20, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, December 5, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, December 5, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, November 15, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, October 31, 2023 | ELECTRONIC RECORD REVIEW COMPLETE |
| Friday, October 27, 2023 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Tuesday, October 24, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, August 7, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, August 7, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, August 7, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, June 6, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, June 6, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, June 6, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, May 11, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 11, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 11, 2023 | ASSIGNED TO LIE |
| Wednesday, February 8, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sunday, September 25, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, September 25, 2022 | NON-FINAL ACTION E-MAILED |
| Sunday, September 25, 2022 | NON-FINAL ACTION WRITTEN |
| Monday, September 12, 2022 | ASSIGNED TO EXAMINER |
| Monday, December 6, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, December 6, 2021 | NEW APPLICATION ENTERED |